FGF19 and primary biliary cholangitis: Indeed, NGM282, an engineered form of human FGF19, has been shown to robustly decrease serum C4 levels and significantly reduce ALP levels in a recent phase II clinical study of PBC patients unresponsive to UDCA treatment [26].